Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. - Wikidata - wikimedia - TriplyDB

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.

http://www.wikidata.org/entity/Q34013315

about

Small molecule inhibitors of zinc-dependent histone deacetylases Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetrance of known and novel small molecule inhibitors in rat.Class I HDAC imaging using [ (3)H]CI-994 autoradiography Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.Antidepressant action of HDAC inhibition in the prefrontal cortex.Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats.Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA.DNA methylation and childhood maltreatment: from animal models to human studies.Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity.Toxicological and metabolic considerations for histone deacetylase inhibitors.11CO2 fixation: a renaissance in PET radiochemistry.Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.Targeting of histone deacetylases in brain tumors.Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.Entinostat for the treatment of breast cancer.Entinostat: a promising treatment option for patients with advanced breast cancer.Epigenetic drugs for Alzheimer's disease: hopes and challenges.Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.ΔFosB Regulates Gene Expression and Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease.18F-Radiolabeled Panobinostat Allows for Positron Emission Tomography Guided Delivery of a Histone Deacetylase Inhibitor.

P2860

Q26824515-6CF949E1-47F5-48FB-9E07-4F94737E6BAE Q26862755-620D4E58-94CA-4485-A553-A4F3B64A1818 Q28066107-7495D576-9D5E-44A6-A216-09BD675A334A Q28535325-6C6B42EC-172D-40A8-A583-6B22AAA3C7EF Q30591009-C1E77189-BA69-4FF5-BF59-0D1150629EE6 Q33556502-AF5285D0-6B12-4A6A-B792-A1DCECDDF657 Q33635942-1AC67C55-B5E6-475F-8F7B-9B0B54F42C16 Q33918201-40B266E0-1DE3-4E6C-89EB-4901D6264421 Q34343350-84CE62AF-B7A0-4D16-B2C0-77357BE1C5C3 Q34353711-E3BC18A3-F7B7-4024-802F-72D934748A4F Q34395031-E66BC4BF-7869-4EAB-98E5-317DAD6708CB Q34467002-DBF47161-18AD-48D5-AB94-008C87C66FD7 Q35638873-21FC9828-F094-4242-8118-D04404111FD7 Q35921399-93F86CF6-3402-41EE-BD33-100E18650EC8 Q36077200-8CB7BD5F-859E-4FBF-83EB-D8208FB560DD Q36520153-DB9BD171-AC35-4E65-A400-90C1E48C24C6 Q37626764-E8FAA8FE-9202-432A-86A0-C6735DE891CB Q37872394-0292612B-3289-42BB-A7B1-F1D7F8407F7A Q38071321-F52E06D2-D1ED-436B-9CF0-D37674BF364D Q38106855-0A8DD7E8-5AAD-4B9E-BAF2-B87C5D56C3C9 Q38136307-815C8EBC-1955-41D8-8522-CC009C34AD51 Q38233117-814A58C2-A4B9-44B0-BD77-CF1A9D94302C Q38534163-82DC9194-4CD7-41FE-86BF-43E98F15310A Q38674317-AFD881D4-A3C5-462E-9EC1-B5ABB032D67E Q38741783-5817DBE4-6B4A-4AF1-A5E4-AA7AF8D4E458 Q39456708-4CDD5AB1-B992-4506-98A5-E0A84316F5DB Q40783140-81B23FCB-48DA-4536-BF5F-3435FF0F0591 Q41862863-3C9053BD-6267-4F8C-8703-80EB4F853E12 Q42008382-62644B87-0835-41FB-958F-FE801E86C503 Q45754556-91B75E1A-C333-4FA9-BBC8-6A95CA86A16E Q48199243-364DB073-DB07-4BED-B899-DEF22A98E5F4 Q49874378-E5FD69D9-1612-48CC-AB05-32D1E6338DC5

P2860

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.

http://www.wikidata.org/entity/Q34013315

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@ast

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@en

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@nl

type

label

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@ast

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@en

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@nl

prefLabel

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@ast

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@en

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@nl

P1433

Q34013315-ED34C8D1-D9BC-470B-9C36-A459F4AC1386

P1476

Q34013315-A6507B64-7A02-422C-9A43-868049E1E1F6

P2093

Q34013315-2C325911-C5D9-4B77-9287-FDE2503974AD

Q34013315-355AF3A7-8D72-4828-909F-E2B39DE1D0DF

Q34013315-8DEA21D7-7B30-45ED-A2CC-924300D9BBCE

Q34013315-9D7072CC-2B47-4651-A801-1251B2ED941C

Q34013315-A62F516F-6775-4602-A14C-5FC77536836F

Q34013315-A6E40A65-C241-421F-BEA3-71DF04557144

P2860

Q34013315-1A39911C-3E3D-4738-9FC5-B9740785CCA8

Q34013315-1C8FDD91-0451-4184-862B-445CC76303FA

Q34013315-2CE4AB3A-0C21-425F-8E7D-95DCE50461B4

Q34013315-2E7DC02E-2FB9-49EB-AC17-CF715C590E4C

Q34013315-452131FF-933C-414C-BEC6-A13A27807D25

Q34013315-45E60A86-6097-4DA4-86A3-1D63B17D3B0A

Q34013315-4C25556B-BE03-48ED-A986-027EAB83CB48

Q34013315-4DADF6D6-3D1E-419F-A96C-4F27CD564F74

Q34013315-58C43779-25C1-4B90-A2A9-23C296C14391

Q34013315-6263A70A-3A92-48EB-AAD9-5C0DD3C0AE34

P304

Q34013315-C1F41D55-23C5-4CCC-9E6D-6A7ACD676761

P31

Q34013315-C3B29AB2-4292-488B-A067-733D940F767C

P356

Q34013315-FEF0EF0A-61B9-4745-AB7D-356C6D184175

P433

Q34013315-EB5BC4FC-8A5C-4703-AD42-8484627459A5

P478

Q34013315-470480FB-5E31-4E9A-9998-ED81705F5FA9

P50

Q34013315-24315AC1-96A2-4EAD-8039-F58156066B05

Q34013315-4BC05F98-D9D9-4FF6-8371-82E036580279

P577

Q34013315-09D2C8F7-E2AD-44FF-92D7-F9D0B8168B77

P5875

Q34013315-7AB94F2B-B0C7-4527-ABC7-112EF090B1A9

P698

Q34013315-5F206804-BD1F-4457-86B6-1D6841D95320

P932

Q34013315-6769AF58-EA7C-477A-82CB-1CCE15814BF3

P356

P1433

ACS Chemical Neuroscience

P1476

Histone deacetylase inhibitor, ...... Positron Emission Tomography.

@en

P2093

Alicia Reid

http://www.w3.org/2001/XMLSchema#string

Colleen Shea

http://www.w3.org/2001/XMLSchema#string

David Alexoff

http://www.w3.org/2001/XMLSchema#string

Joanna S Fowler

http://www.w3.org/2001/XMLSchema#string

Sung Won Kim

http://www.w3.org/2001/XMLSchema#string

Youwen Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

HDAC2 negatively regulates memory formation and synaptic plasticity.

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

Rational development of histone deacetylase inhibitors as anticancer agents: a review.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

P304

65-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/CN9000268

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Jacob M. Hooker

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45288591

http://www.w3.org/2001/XMLSchema#string

P698

20657706

http://www.w3.org/2001/XMLSchema#string

P932

2908422

http://www.w3.org/2001/XMLSchema#string